keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/29777744/omalizumab-can-inhibit-respiratory-reaction-during-aspirin-desensitization
#1
David M Lang, Mark A Aronica, Elizabeth S Maierson, Xiao-Feng Wang, Dorothy C Vasas, Stanley L Hazen
BACKGROUND: Aspirin desensitization has been associated with benefit in management of aspirin exacerbated respiratory disease (AERD). An intervention that would encourage aspirin desensitization to be performed more frequently has substantial potential for improving outcomes and quality of life in patients with AERD. OBJECTIVE: We investigated whether omalizumab administration would be associated with attenuation of aspirin-provoked bronchospasm in patients with AERD undergoing aspirin desensitization...
May 16, 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29772578/long-term-omalizumab-treatment-a-multicenter-real-life-5-year-trial
#2
Arzu Yorgancıoğlu, Ferda Öner Erkekol, Dilşad Mungan, Münevver Erdinç, Bilun Gemicioğlu, Zeynep Ferhan Özşeker, Papatya Bayrak Değirmenci, Sibel Naycı, Aykut Çilli, Füsun Erdenen, Cengiz Kırmaz, Dane Ediger, Arzu Didem Yalçın, Suna Büyüköztürk, Sami Öztürk, Mustafa Güleç, Sacide Rana Işık, Ali Fuat Kalyoncu, Özlem Göksel, Ömür Aydın, Yavuz Havlucu, İdilhan Baloğlu Ar, Ahmet Erdoğdu
BACKGROUND: Omalizumab has demonstrated therapeutic benefits both in controlled clinical trials and real-life studies. However, research concerning the long-term effects and tolerability of omalizumab is needed. The main objective of this study was to evaluate the effectiveness and tolerability of treatment with omalizumab for up to 5 years. METHODS: A multicenter, retrospective, chart-based study was carried out to compare documented exacerbations, hospitalizations, systemic steroid requirement, FEV1, and asthma control test (ACT) results during 1 year prior to omalizumab treatment versus at 1, 3, and 5 years of treatment...
May 17, 2018: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/29770909/omalizumab-in-chronic-spontaneous-urticaria-refractory-to-conventional-therapy-an-italian-retrospective-clinical-analysis-with-suggestions-for-long-term-maintenance-strategies
#3
Victor D Mandel, Mario B Guanti, Serena Liberati, Antongiulio Demonte, Giovanni Pellacani, Patrizia Pepe
INTRODUCTION: Omalizumab is indicated for the treatment of patients affected by chronic spontaneous urticaria (CSU) refractory to antihistamines. The aim of this study was to assess the efficacy, safety, and recurrence of symptoms in a real-life experience of omalizumab as an add-on therapy for H1 -antihistamine-refractory CSU patients (refractory CSU). METHODS: A retrospective review of the clinical records of all refractory CSU treated with omalizumab at our dermatology center from June 2014 to April 2017 was performed...
May 16, 2018: Dermatology and Therapy
https://www.readbyqxmd.com/read/29768374/treatment-of-multiple-refractory-ankle-ulcerations-in-thromboangiitis-obliterans-a-case-report
#4
Zheng-Hao Huang, San-Yuan Kuo, Yu-Hsiang Chiu, Hsiang-Cheng Chen, Chun-Chi Lu
RATIONALE: Thromboangiitis obliterans (TAOs, or Buerger's disease) present as a non-atherosclerotic segmental occlusive vasculitis within medium- and small-sized blood vessels. TAO frequently occurs in young adults and is associated with cigarette smoking. At present, there are no accurately defined treatments for TAO. PATIENT CONCERNS: A 34-year-old Asian woman with a 20-year history of heavy cigarette smoking and recurrent, small, and self-limited lower limb ulcerations since adolescence, presented with persisting unhealed ulcerations on both ankles for 6 months...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29766394/treatment-of-eosinophilic-granulomatosis-with-polyangiitis-a-review
#5
Loïc Raffray, Loïc Guillevin
Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) is a rare type of anti-neutrophil cytoplasm antibody-associated vasculitis. Nevertheless, eosinophilic granulomatosis with polyangiitis stands apart because it has features of vasculitis and eosinophilic disorders that require targeted therapies somewhat different from those used for other anti-neutrophil cytoplasm antibody-associated vasculitides. Considerable advances have been made in understanding the underlying pathophysiology of eosinophilic granulomatosis with polyangiitis that have highlighted the key role of eosinophils and opened new therapeutic opportunities...
May 15, 2018: Drugs
https://www.readbyqxmd.com/read/29764789/eosinophilic-otitis-media-treated-with-anti-ige-monoclonal-antibodies-and-a-bone-conduction-implant
#6
Young Eun Han, Yong Seok Kang, Younhoon Cho, Moo Kyun Park
Eosinophilic otitis media (EOM) are intractable otitis media characterized by highly viscous secretions containing eosinophils in the middle ear. They are resistant to conventional medication and surgery. This condition occurs primarily in patients with bronchial asthma or allergic rhinitis and is often complicated by rhinosinusitis. Systemic and topical steroid therapies are effective treatments. However, long-term steroid therapy is often limited by a high risk of serious adverse effects. The use of topical steroids and otorrhea are bothersome when wearing hearing aids...
April 2018: Journal of International Advanced Otology
https://www.readbyqxmd.com/read/29753833/efficacy-of-a-single-dose-of-omalizumab-for-the-prevention-of-ethylene-oxide-intraoperative-anaphylaxis
#7
Maria Beatrice Bilò, Alice Corsi, M Feliciana Brianzoni, M Stella Garritani, Leonardo Antonicelli
No abstract text is available yet for this article.
May 10, 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29748244/are-peripheral-blood-eosinophil-counts-a-guideline-for-omalizumab-treatment-stellair-says-no
#8
EDITORIAL
William W Busse
No abstract text is available yet for this article.
May 2018: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/29744661/update-on-omalizumab-for-urticaria-what-s-new-in-the-literature-from-mechanisms-to-clinic
#9
REVIEW
Désirée E S Larenas-Linnemann, Claudio A S Parisi, Carla Ritchie, Ricardo Cardona-Villa, Ivan Cherrez-Ojeda, Annia Cherrez, Luis Felipe Ensina, Elizabeth Garcia, Iris V Medina, Mónica Rodríguez-González, Jorge Mario Sánchez Caraballo
PURPOSE OF REVIEW: Since omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017-February 2018. RECENT FINDINGS: Omalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline ≥2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/month; however, others are still not controlled with 300 mg/month...
May 9, 2018: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/29741411/biomarkers-for-severe-allergic-asthma-in-children-could-they-be-useful-to-guide-disease-control-and-use-of-omalizumab
#10
Flore Amat, André Labbé
Although symptom controls in asthmatic children can be achieved through compliant use of conventional medication, some children have uncontrolled severe persistent asthma, especially if they are allergic. For these children, omalizumab (approved by the EMA and FDA in children aged > 6 years) could be a therapeutic option. However, response to omalizumab varies from one child to another. Predictive biomarkers of omalizumab effectiveness could be useful to monitor response to treatment. Area covered: The authors searched in the PubMed database for publications related to the use of biomarkers in allergic asthma...
May 16, 2018: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/29737044/a-clinical-follow-up-of-omalizumab-in-routine-treatment-of-allergic-asthma-monitored-by-cd-sens
#11
S Gunnar O Johansson, Gunnar Lilja, Jenny Hallberg, Anna Nopp
INTRODUCTION: Omalizumab has been available for treatment of allergic asthma for more than a decade and thus, its efficacy in routine treatment was of interest to evaluate. Basophil allergen threshold sensitivity (CD-sens) has been shown to correlate with the bronchial allergen threshold sensitivity and can be used to objectively measure omalizumab treatment efficacy. We aimed to evaluate the effect of omalizumab treatment of allergic asthma by CD-sens, as an objective marker of the IgE-mediated inflammation, and related to SPT, spirometry, FeNO, Asthma Control Questionnaire (ACQ), and Global Evaluation of Treatment Effectiveness (GETE)...
May 7, 2018: Immunity, Inflammation and Disease
https://www.readbyqxmd.com/read/29736895/cost-effectiveness-of-biological-asthma-treatments-a-systematic-review-and-recommendations-for-future-economic-evaluations
#12
REVIEW
R Brett McQueen, Danielle N Sheehan, Melanie D Whittington, Job F M van Boven, Jonathan D Campbell
BACKGROUND: Recently developed asthma biological therapies have been shown to provide relief for severe asthma patients not controlled by inhaled treatment. Given the relatively high costs of biological therapies, cost-effectiveness analyses (CEAs) may be required as a prerequisite for coverage and reimbursement. OBJECTIVE: We aimed to systematically review published literature on the economic impact of biological asthma therapies and to identify key drivers that impact cost-effectiveness in order to provide recommendations for future economic evaluations...
May 8, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29733738/case-study-a-combination-of-mepolizumab-and-omaluzimab-injections-for-severe-asthma
#13
Rejmon Dedaj, Lindie Unsel
A Combination of Mepolizumab and Omaluzimab injections for severe asthma. INTRODUCTION: Patients with severe persistent asthma account for a large proportion of asthma morbidity and health care expenditures. In this case report we describe the use of a combination of omalizumab and mepolizumab in severe asthma with elevated IgE levels and eosinophilic phenotype. CASE STUDY: We are treating a 55 year old woman with severe persistent eosinophilic asthma and elevated IgE levels...
May 7, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29729103/effectiveness-of-omalizumab-in-chronic-spontaneous-urticaria-assessed-with-patient-reported-outcomes-a-prospective-study
#14
Misbah Noshela Ghazanfar, Jesper Grønlund Holm, Simon Francis Thomsen
AIM: To examine the effectiveness of omalizumab (anti-IgE) on symptoms and disease-related quality of life in chronic spontaneous urticaria (CSU), and to identify possible patient specific factors associated with response to omalizumab in patients with antihistamine refractory CSU. METHODS: Six months prospective trial of omalizumab 300 mg every four weeks among patients with CSU from a dermatological university department. The primary outcome was the urticaria activity score in the past week (UAS7) at three months...
May 5, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29723352/urticaria-and-angioedema-as-possible-reactions-of-omalizumab
#15
Ozlem Ozbagcivan, Sevgi Akarsu, Turna Ilknur, Emel Fetil
No abstract text is available yet for this article.
March 2018: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/29714140/omalizumab-in-the-therapy-of-pediatric-asthma
#16
Dimitri Poddighe, Ilaria Brambilla, Amelia Licari, Gian Luigi Marseglia
BACKGROUND: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immune- pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma. OBJECTIVE: in this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma, Furthermore, we provided the main practical points for such a therapeutic management...
April 30, 2018: Recent Patents on Inflammation & Allergy Drug Discovery
https://www.readbyqxmd.com/read/29713354/severe-eosinophilic-asthma-in-primary-care-in-canada-a-longitudinal-study-of-the-clinical-burden-and-economic-impact-based-on-linked-electronic-medical-record-data
#17
Don Husereau, Jason Goodfield, Richard Leigh, Richard Borrelli, Michel Cloutier, Alain Gendron
Background: Stratification of patients with severe asthma by blood eosinophil counts predicts responders to anti-interleukin (IL)-5 (mepolizumab and reslizumab) and anti-IL-5 receptor α (benralizumab) therapies. This study characterized patients with severe asthma who could qualify for these biologics in a primary care setting. Methods: We retrospectively selected patients from July 1, 2010, to June 30, 2014, using a linked electronic medical records (EMR) database (IMS Evidence 360 EMR Canada) for > 950,000 patients in primary care in Ontario, Canada...
2018: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/29707773/wells-syndrome-a-case-of-successful-treatment-with-omalizumab
#18
Øystein Egeland, Flora Balieva, Erling Undersrud
No abstract text is available yet for this article.
April 29, 2018: International Journal of Dermatology
https://www.readbyqxmd.com/read/29700872/oral-immunotherapy-with-omalizumab-reverses-the-th2-cell-like-program-of-regulatory-t-cells-and-restores-their-function
#19
Azza Abdel-Gadir, Lynda Schneider, Arianna Casini, Louis-Marie Charbonnier, Sara V Little, Timothy Harrington, Dale T Umetsu, Rima Rachid, Talal A Chatila
BACKGROUND: Oral immunotherapy (OIT) successfully desensitizes patients with food allergies, but the immune mechanisms mediating its efficacy remain obscure. OBJECTIVES: We tested the hypothesis that allergen-specific regulatory T (Treg) cell function is impaired in food allergy and is restored by anti-IgE antibody (omalizumab)-supplemented OIT. METHODS: Peanut-specific T effector (Teff) and Treg cell proliferative responses, activation markers and cytokine expression were analyzed by flow cytometry in 13 peanut allergic subjects before the start of omalizumab- supplemented OIT and periodically in some subjects thereafter for up to two years...
April 27, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29672188/effect-of-inhaled-corticosteroid-use-on-weight-bmi-in-pediatric-patients-with-moderate-severe-asthma
#20
Jennifer Han, John Nguyen, Yuna Kim, Bob Geng, Gale Romanowski, Lawrence Alejandro, James Proudfoot, Ronghui Xu, Sydney Leibel
OBJECTIVES: Assess the relationship between inhaled corticosteroid use (ICS) and weight (BMI) in pediatric patients with moderate-severe asthma. Assess if the number of emergency department (ED) visits correlates with overall BMI trajectory. Assess the trend of prescribing biologic therapy in pediatric patients with moderate-severe asthma and determine its relationship with weight (BMI). METHODS: A retrospective chart review was performed on 93 pediatric patients with moderate-severe asthma to determine the relationship between ICS use and weight (BMI), biologic therapy and BMI, and number of ED visits and BMI trajectory...
April 19, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"